Cargando…
BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with canc...
Autores principales: | Ehmsen, Sidse, Pedersen, Rune M., Bang, Line L., Asmussen, Anders, Kragh, Amalie, Holm, Dorte K., Sydenham, Thomas V., Jensen, Thøger G., Jeppesen, Stefan S., Frederiksen, Henrik, Andersen, Thomas E., Ditzel, Henrik J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910012/ https://www.ncbi.nlm.nih.gov/pubmed/36804967 http://dx.doi.org/10.1016/j.ccell.2023.02.003 |
Ejemplares similares
-
Serum Neutralization of Omicron XBB.1.5 in Kidney Transplant Recipients After Bivalent mRNA Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2023) -
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
por: Davis-Gardner, Meredith E., et al.
Publicado: (2022) -
Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023) -
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023) -
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)